Drug intelligence / Profile preview

LZ901

Development stage: Phase 3
Lead developer: Beijing Luzhu Biotechnology
Modality: Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

LZ901 is a recombinant herpes zoster vaccine featuring a unique tetrameric molecular structure. It consists of a tetramer of varicella zoster virus (VZV) glycoprotein E (gE) and a human IgG1 Fc fusion protein expressed in CHO cells and adsorbed with aluminum hydroxide adjuvant. The fusion protein is formed by an extracellular domain of the recombinant glycoprotein gE of a live attenuated VZV strain (Oka) and an Fc fragment of human immunoglobulin. Unlike live attenuated virus vaccines, this recombinant protein vaccine induces an immune response while avoiding risks of residual virulence. It requires two injections per treatment without needing a third booster shot.

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on LZ901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LZ901.